Compare AstraZeneca plc (AZN) vs SpaceX (SPCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs SpaceX — how do they compare? AstraZeneca plc trades at $158.6 (market cap $248.14B), while SpaceX trades at $148.1 (market cap $1.76T). The key difference: SpaceX is far larger — about 7.1× AstraZeneca plc's market cap, and AstraZeneca plc pays a 2.01% dividend while SpaceX pays none. Which is the better fit depends on your goals.
| AZN | SPCX | |
|---|---|---|
Market Cap | $248.14B | $1.76T |
Sector | Health | Technology |
52-Week High | $209.48 | $202.09 |
52-Week Low | $147.06 | $108.27 |
Enterprise Value | $275.41B | $1.70T |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
SPCX stock trades at $147.99, up 6.67% today, with a bullish technical signal and strong analyst support. Recent news highlights AI growth and a $1.2 billion stake by Norway's sovereign wealth fund. However, the company shows negative net income margins and high valuation ratios, with revenue growth offset by profitability challenges.
The outlook is mixed: bullish sentiment and AI expansion offer upside, but high valuation and persistent losses pose risks. The consensus price target of $228.52 suggests potential growth, yet investors must weigh innovation against financial sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About SpaceX
SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →
